NCT00686634

Sitagliptin in Combination With Metformin and Sulfonylurea

Sitagliptin in Combination Oral Agent Therapy for Type 2 Diabetes

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 108 (actual)
• Sponsor: Charles Drew University of Medicine and Science · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will compare the effect of a new oral agent for type 2 diabetes, sitagliptin, in comparison to thiazolidinediones as the third-line oral agent, in patients with type 2 diabetes mellitus.

Detailed description

The aim of this protocol is to determine the non-inferiority of the effectiveness of sitagliptin compared to a control group of patients treated with thiazolidinediones as add-on therapy, in low-income ethnic minority type 2 diabetic patients who are failing to maintain adequate control with maximal doses of metformin and a sulfonylurea agent.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Sitagliptin	Sitagliptin 100 mg by mouth once daily

Timeline

• Start date: 2008-01-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2008-05-30
• Last updated: 2014-11-26
• Results posted: 2014-11-26

Locations

1 site across 1 country: United States